206 related articles for article (PubMed ID: 26959415)
1. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.
Weiner M; Skoog L; Fornander T; Nordenskjöld B; Sgroi DC; Stål O
Ann Oncol; 2013 Aug; 24(8):1994-9. PubMed ID: 23670096
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
5. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
7. Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.
Jögi A; Ehinger A; Hartman L; Alkner S
PLoS One; 2019; 14(12):e0226150. PubMed ID: 31821370
[TBL] [Abstract][Full Text] [Related]
8. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
9. [The relationship between the expression of amplified in breast cancer 1、androgen receptor and tamoxifen resistance in breast cancer].
Liu N; Meng QX; Wang GS
Zhonghua Yi Xue Za Zhi; 2023 May; 103(20):1553-1559. PubMed ID: 37246005
[No Abstract] [Full Text] [Related]
10. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
11. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
12. The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer.
Kaas R; Peterse JL; Hart AA; Voogd AC; Rutgers EJ; van Leeuwen FE
Br J Cancer; 2003 Mar; 88(5):707-10. PubMed ID: 12618879
[TBL] [Abstract][Full Text] [Related]
13. AIB1 is a predictive factor for tamoxifen response in premenopausal women.
Alkner S; Bendahl PO; Grabau D; Lövgren K; Stål O; Rydén L; Fernö M;
Ann Oncol; 2010 Feb; 21(2):238-244. PubMed ID: 19628566
[TBL] [Abstract][Full Text] [Related]
14. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
17. Expression of AIB1 protein as a prognostic factor in breast cancer.
Lee K; Lee A; Song BJ; Kang CS
World J Surg Oncol; 2011 Oct; 9():139. PubMed ID: 22035181
[TBL] [Abstract][Full Text] [Related]
18. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
[TBL] [Abstract][Full Text] [Related]
19. The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
Alkner S; Bendahl P; Grabau D; Malmström P; Fernö M; Rydén L;
Ann Oncol; 2013 May; 24(5):1244-52. PubMed ID: 23230135
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
